The Kidney Patient’s Unmet Clinical Need

How Vascular Therapies is Addressing the Need

Local Drug Delivery

Vascular Therapies’ approach is to deliver sirolimus (a drug) locally to the blood vessel at and around the anastomosis. It is doing so by implanting a collagen-based drug delivery system containing sirolimus at the time of the surgical procedure. Vascular Therapies’ goal: to prevent the veins from narrowing, keep the portal open and provide for consistent vascular access necessary for successful dialysis.

Vascular Therapies Announces Preliminary Results from its Phase 3 AV Fistula Study

At the annual meeting of the American Society of Nephrology (ASN), Vascular Therapies, Inc. presented preliminary results relating to analysis of the first 18 (open-label) patients from its U.S. Phase 3 study. The results suggest this investigational treatment approach may reduce a patient’s dependence on the extended use of catheters – the way most patients begin dialysis treatment.

Learn More
Vascular Therapies now in phase 3 clinical trials

Caution: The Sirolimus-eluting Collagen Implant is an investigational product that is not available for sale in any country.
Read our Expanded Access Policy.